A New Medical Breakthrough In Diabetic Treatment
The IANS (Indo-Asian News Service) shared information about studies related to diabetic treatment. Recent studies have revolutionised diabetic treatment. Studies share information about medicinal drugs that will protect diabetic patients against heart and kidney disease.
Studies have shown that the combination of sodium-glucose co-transporters, 2 inhibitors (SGLT2is), and glucagon-like peptide-1 receptor agonists (GLP1-RAs) can protect against heart and kidney disease in diabetes patients.
The SGLT2is drug, also known as gliflozins, is a class of drugs that decreases blood glucose by raising its excretion in the urine. GLP-1RAs like Ozempic enhance insulin release and their sensitivity to lower blood sugar levels.
If someone’s glucose falls between 140 and 199 mg/dL, they have an impaired glucose tolerance. It can cause damage to blood vessels in the heart and kidneys in diabetes patients.
Brendon Neuen, the lead author and Nephrologist at Royal North Shore Hospital, says that “the rapidly expanding indications for the use of GLP-1 receptor agonists, makes it important to look at their effects with SGLT2 inhibitors.”
The new findings, released by The Lancet Diabetes & Endocrinology, are based on a meta-analysis of 12 broad, placebo-controlled trials of SGLT2is. This trial included 73,238 diabetic patients, and 3065 of them were already taking GLP1-RAs. The results revealed that SGLT2is lowered the risk of heart attack, stroke, or cardiovascular death by 11%.
Further, the SGLT2is drug lowered chronic kidney disease progression risk by 33% when added to GLP1-RAs. When combined with GLP-1RAs, it slowed the annual loss of kidney function by 69%. The SGLT2is drug also decreased hospitalisation for heart failure or cardiovascular death by 23%.
Brendon Neuen shared that both categories of medicines work independently. SGLT2is work against heart failure and chronic kidney disease, and GLP-1 RAs work against heart attack, stroke, and kidney disease.